Kazumi Shiosaki, Ph.D., joined MPM’s Boston office in 2003. Her interests and expertise include identifying companies and technologies in novel drug discovery areas. Kazumi has helped to found and served as the start-up CEO of several MPM companies including Primera Diagnostics, Epizyme, and most recently Mitokyne. She serves on the boards, as well as scientific advisory boards, of several MPM portfolio companies.

Kazumi brings extensive strategic and operational experience in the pharmaceutical-biotechnology industry with a career that began at Abbott Laboratories (now AbbVie) where she managed a number of programs in various therapeutic areas. As SVP of Drug Discovery at Millennium Pharmaceuticals, she helped lead the efforts to transition Millennium from a genomics into a drug discovery organization and was part of the team that secured as well as implemented large, precedent-setting pharma partnerships. Kazumi received her Ph.D. in Synthetic Chemistry from the University of California, Berkeley, and a B.S. in Chemistry from Whitman College.

Fund's investment verticals: biotechnology, health care and medical device.